Evidence map›Paper›PMID 41196694›Full record

ArticleJCI insight2025

A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion.

Carolina M Larrain, Jack H Victory, Priyanka P Desai, Lindsay R Friedman, Hannah Stepp, Rachel Ashe, Kirsten Remmert, Surajit Sinha, Emily C Smith, Nicole Russell and 9 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07715903 (Phase I Study Evaluating Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07715903 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase I Study Evaluating Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2026 to 2031Enrolled20ConditionsColorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical CarcinomaArmsCarfilzomib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Carolina M LarrainSurgical Oncology Program.
Jack H VictorySurgical Oncology Program.
Priyanka P DesaiSurgical Oncology Program.
Lindsay R FriedmanSurgical Oncology Program.
Hannah SteppSurgical Oncology Program.
Rachel AsheGenitourinary Malignancies Branch, and.
Kirsten RemmertSurgical Oncology Program.
Surajit SinhaSurgical Oncology Program.
Emily C SmithSurgical Oncology Program.
Nicole RussellSurgical Oncology Program.
Tracey PuSurgical Oncology Program.
Alyssa V EadeSurgical Oncology Program.
Justine F BurkeSurgical Oncology Program.
Jason HoSurgical Oncology Program.
Michael B YaffeSurgical Oncology Program.
David E KleinerLaboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Keith SchmidtGenitourinary Malignancies Branch, and.
William D FiggGenitourinary Malignancies Branch, and.
Jonathan M HernandezSurgical Oncology Program.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting tumors with proteosome inhibitors has demonstrated antitumor activity and has been successfully translated to the clinic for patients with multiple myeloma. However, in patients with solid tumors, treatment with proteosome inhibitors as single agents has consistently failed to yield meaningful responses. In our study, we investigate the potential of hepatic artery infusion pump delivery of carfilzomib, to continuously direct a large dose to the tumor with least hepatic toxicity.

Indexed as

Antineoplastic AgentsNeoplasmsOligopeptidesProteasome InhibitorsAnimalsCell Line, TumorFemaleHepatic ArteryHumansInfusions, Intra-ArterialMaleMiceXenograft Model Antitumor AssaysAntineoplastic AgentscarfilzomibOligopeptidesProteasome InhibitorsColorectal cancerHepatologyOncology

Identifiers

PMID41196694
PMCPMC12890499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.